Walser Wealth Management Company A Ltd Liability Co Takes $592,000 Position in Bristol Myers Squibb Company $BMY

Walser Wealth Management Company A Ltd Liability Co bought a new position in shares of Bristol Myers Squibb Company (NYSE:BMY) during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor bought 9,758 shares of the biopharmaceutical company’s stock, valued at approximately $592,000.

A number of other hedge funds also recently added to or reduced their stakes in the business. Brighton Jones LLC boosted its stake in shares of Bristol Myers Squibb by 33.4% in the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock valued at $1,116,000 after buying an additional 4,935 shares during the period. Sivia Capital Partners LLC increased its stake in shares of Bristol Myers Squibb by 59.4% during the second quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock worth $346,000 after buying an additional 2,786 shares during the period. United Bank raised its holdings in Bristol Myers Squibb by 15.0% in the second quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock valued at $1,164,000 after acquiring an additional 3,277 shares in the last quarter. Marshall Wace LLP acquired a new stake in Bristol Myers Squibb in the second quarter valued at approximately $221,000. Finally, Nebula Research & Development LLC purchased a new position in Bristol Myers Squibb in the second quarter worth approximately $405,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

BMY has been the subject of several analyst reports. HSBC increased their price objective on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the company a “hold” rating in a research report on Tuesday, March 17th. UBS Group reaffirmed a “buy” rating on shares of Bristol Myers Squibb in a research report on Thursday, May 28th. Bank of America lowered their target price on shares of Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating for the company in a research note on Thursday, April 9th. Weiss Ratings restated a “hold (c+)” rating on shares of Bristol Myers Squibb in a research note on Thursday. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $54.00 price target on shares of Bristol Myers Squibb in a report on Monday. Eight research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $61.31.

Bristol Myers Squibb Stock Up 2.8%

BMY stock traded up $1.57 during midday trading on Tuesday, reaching $58.27. 2,245,915 shares of the company were exchanged, compared to its average volume of 12,378,629. The company has a market cap of $118.99 billion, a price-to-earnings ratio of 16.37, a price-to-earnings-growth ratio of 0.17 and a beta of 0.23. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $62.89. The stock’s 50-day simple moving average is $56.90 and its 200 day simple moving average is $57.51.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The business had revenue of $11.49 billion during the quarter, compared to analysts’ expectations of $10.93 billion. During the same quarter in the prior year, the business posted $1.80 EPS. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities analysts forecast that Bristol Myers Squibb Company will post 6.32 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, July 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.3%. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 70.79%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.